Kijak, G., Ahani, B., Arbetter, D., Chuecos, F., Gopalakrishnan, V., Beloor, J., . . . Streicher, K. (2023). Analysis of SARS-CoV-2 Emergent variants following AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19 (TACKLE trial). Springer Nature.
Citación estilo ChicagoKijak, GH, et al. Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (tixagevimab/cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial). Springer Nature, 2023.
Cita MLAKijak, GH, et al. Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (tixagevimab/cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial). Springer Nature, 2023.
Warning: These citations may not always be 100% accurate.